ストックスクリーナーアプリを入手
0.6467
6.02%
0.0367
アフターアワーズ：
.65
0.0033
+0.51%
前日終値:
$0.61
開ける：
$0.635
24時間の取引高:
127.79K
Relative Volume:
0.60
時価総額：
$8.99M
収益：
$17.44M
当期純損益:
$-21.23M
株価収益率:
-0.2892
EPS:
-2.2361
ネットキャッシュフロー:
$-17.60M
1週間 パフォーマンス:
+10.53%
1か月 パフォーマンス:
-23.23%
6か月 パフォーマンス:
-71.13%
1年 パフォーマンス:
-71.64%
1日の値動き範囲:
$0.6198
$0.6574
1週間の範囲:
$0.545
$0.6614
52週間の値動き範囲:
$0.545
$7.95
Vivos Therapeutics Inc Stock (VVOS) Company Profile
名前
Vivos Therapeutics Inc
セクター
電話
(866)908-4867
住所
7921 SOUTHPARK PLAZA,, LITTLETON
Compare VVOS vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VVOS
Vivos Therapeutics Inc
|
0.6467 | 8.48M | 17.44M | -21.23M | -17.60M | -2.2361 |
ABT
Abbott Laboratories
|
86.67 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
313.00 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.60 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.64 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.54 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
Vivos Therapeutics Inc (VVOS) 最新ニュース
Vivos Therapeutics Balances Rapid Growth With Cash Strain - TipRanks
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q1 2026 Earnings Call Transcript - Insider Monkey
Vivos Therapeutics Earnings Call: Growth Meets Cash Strain - TipRanks
Vivos Therapeutics, Inc. 1Q 2026: Revenue $5.14M, EPS $(0.52) — 10-Q Summary - TradingView
Vivos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Vivos Therapeutics (NASDAQ: VVOS) Q1 2026 loss and going concern risk - Stock Titan
Vivos Therapeutics reports 70% revenue increase in Q1 2026 - Investing.com
Vivos Therapeutics reports 70% revenue increase in Q1 2026 By Investing.com - Investing.com Canada
Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update - The Manila Times
BRIEF-Vivos Therapeutics Q1 Net Income USD -7.751 Million - TradingView
Press Release: Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update - Moomoo
VVOS Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Vivos Therapeutics Delays Quarterly Filing - TipRanks
Vivos Therapeutics (VVOS) delays Q1 10-Q; preliminary revenue up ~70% - Stock Titan
Armistice Capital (NASDAQ: VVOS) reports 8.27% holding in Vivos Therapeutics - Stock Titan
VVOS Stock Chart | VIVOS THERAPEUTICS INC (NASDAQ:VVOS) - ChartMill
TradingKey - TradingKey
[EFFECT] Vivos Therapeutics, Inc. SEC Filing - Stock Titan
Vivos targets cash flow positive operations by end of 2026 as it scales SO teams with $500,000+ monthly collections potential - MSN
Vivos Therapeutics Faces Nasdaq Listing Compliance Challenges - TipRanks
3.96M warrant shares registered by Vivos (VVOS) for resale; $2.09 strike - Stock Titan
VVOS Forecast, Price Target & Analyst Ratings | VIVOS THERAPEUTICS INC (NASDAQ:VVOS) - ChartMill
Vivos Therapeutics (VVOS) price target decreased by 51.67% to 2.47 - MSN
Broadcom, Vivos Therapeutics and 3 stocks to watch heading into Monday - MSN
Vivos Therapeutics (NASDAQ: VVOS) registers 3.96M warrant-linked shares for resale - Stock Titan
VVOS Should I Buy - Intellectia AI
Vivos Therapeutics receives Nasdaq notice for stockholders’ equity deficiency - Investing.com
Vivos Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Equity shortfall puts Vivos Therapeutics (NASDAQ: VVOS) at Nasdaq delisting risk - Stock Titan
Qorvo To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Vivos Reports 16% Revenue Increase in 2025 Following Business Model Shift - Sleep Review
Vivos Therapeutics stock price target lowered to $2.50 by H.C. Wainwright - Investing.com Australia
New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM ESTShow #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Viv - ACCESS Newswire
H.C. Wainwright Maintains Vivos Therapeutics(VVOS.US) With Buy Rating, Cuts Target Price to $2.5 - 富途牛牛
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2025 Earnings Call Transcript - Insider Monkey
Vivos Therapeutics (VVOS) Stock: Why Cash Position (Freefalls) 2026-04-16Trending Entry Points - UBND thành phố Hải Phòng
Vivos Therapeutics Balances Growth Hopes With Cash Strain - TipRanks
Vivos Therapeutics Reports Full Year 2025 Financial Results - ADVFN
Vivos Therapeutics Inc (VVOS) Q4 2025 Earnings Call Highlights: Revenue Growth Amid Strategic ... By GuruFocus - Investing.com Canada
Vivos Therapeutics Pivots to Medical-Provider Focused Model with Sleep Center of Nevada Acquisition to Expand Sleep Apnea Solutions 91 - Minichart
Vivos Therapeutics Reports 16% Revenue Growth in 2025, Advances Sleep Center Integration and Eyes Cash Flow Positive Operations - Minichart
Earnings call transcript: vivos beats Q4 2025 earnings expectations - Investing.com UK
VVOS: 2025 revenue rose 16% as SCN integration fueled growth, with further expansion planned for 2026 - TradingView
Earnings Call Summary | Vivos Therapeutics(VVOS.US) Q4 2025 Earnings Conference - 富途牛牛
VVOS: 2025 revenue up 16% from SCN integration, with strong growth outlook as new model scales - TradingView
Earnings call transcript: vivos beats Q4 2025 earnings expectations By Investing.com - Investing.com India
Vivos Therapeutics Inc (VVOS) 財務データ
収益
当期純利益
現金流量
EPS
1.27%
2.05%
大文字化:
|
ボリューム (24 時間):